Rapid Antigen Test Card
Self-test received notified body approved CE marking on Apr.1,2021
A home test for the rapid qualitative detection of antigen in anterior nasal swabs within 7days of symptom onset
â?¢Sample type: nasal swab
â?¢Time to result: 15-20 min
â?¢Sensitivity: 96.77%Specificity: 99.20%Accuracy: 98.72%
â?¢Layperson study statistics:
99.10% of non-professionals carried out the test without requiring
97.87% of different types of results were interpreted correctly
Each Test have Unique Identifier Number - Easy to track
Approved By - UK, Germany, France, Spain, Netherlands, Greece, Belgium, Italy, Portugal.
1 Test / Kit
Catalog No.: 1N40C5-2
Kit Components:
1 Rapid SARS-CoV-2
Antigen Test Card (sealed
foil pouch)
1 sterilized swab
1 extraction tube
1 sample extraction buffer
IFU
Tube holder on back of box
Box / Carton Specifications :
1 Test / Kit
Box size - 190*60*15 mm
Carton size - 42*42*33 cm
250 tests (boxes) / carton
Carton gross weight - 9.9 kg
Price and Minumum Quantity
Price FOB in USD: -Minimum Order Qty: 2000 Pieces
Production Capacity: 10 Million Units A MonthPackaging: Pack Of 1, 5, 20
Product Model And Origin: Xiamen China
Brand: BOSON
For the newly discovered new coronavirus mutant strain Omicron(B.1.1.529),our conducts the sequence comparison analysis of its 32 mutation sites. All mutation sites are outside the epitope region recognized by the new crown paired monoclonal antibody selected by our company.Therefore,according to known academic opinions,the effective production strain for Omicron(B.1.1.529)can still be detected by our product"SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography)"
Next,our will continue to follow up on the mutation of Covid-19perform sequence alignment analysis in timeand evaluate and verify the detection ability of key mutation sites to ensure the sensitivity and specificity of the kit.
The 2019-nCoV Ag Saliva Rapid Test is a lateral flow immunoassav intended for the qualitative detection of nucleocapsid protein antigen from2019-nCoV in saliva specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within the first 7 days of symptom onset
PO from Buyer
CI from Seller
Buyer signs and returns the CI
Seller's Attorney prepared LOA and submits to Buyer
Escrow Agreement from Seller is signed
Buyer escrows funds for full purchase
SGS inspection is performed at buyer's expense
Logistics details are exchanged
Upon confirmed report, escrowed funds are released simultaneous with title transfer
Covid Test from PXY cooperation with public cooperation, CE certificated. Our products are designated by many European governments.
PXY has invested in professional COVID test manufacturers, the COVID test kit we provide, SARS-CoV-2 Antigen Rapid Test Kit, the method used is Colloidal Gold Immunochromatography. Our rapid COVID test kit packed in Card-like format has the following advantage:
* Non-invasive. Swabbed specimens from the nasopharynx or oropharyngeal;
* Rapid, ONLY in 15 minutes can get the result;
* Simple Operation. No more devices required;
* High accuracy and stability. Gold-labeled SARS-CoV-2 N protein monoclonal antibodies immobilized on the test area, with corresponding antibodies in the quality control area;
Product Description
The iHealth COVID-19 Antigen Rapid Test is a lateral flow assay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2.
This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected nasal swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.
This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older, or adult collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.
